Study Group on Translational Radio-Oncology and Ionizing Radiation Therapy

The group serves as a platform to discuss and pioneer research in cutting-edge areas, including:

• Radiopharmaceutical Therapy (RPT): Exploring the use of targeted systemic radioisotopes (e.g., alpha- and beta-emitters) for cancer treatment and optimizing dosimetry and combination strategies for these agents.
• Quantitative radiation biology modeling: Experimenting and creating models for studying radiation-induced damage, including DNA repair kinetics, micro- and nano-dosimetry, by-stander signaling, and whole-organ toxicity.
• Novel Radiosensitizers: Investigating new pharmacological agents and biological pathways to enhance tumor cell killing and overcome resistance to radiation.
• The Immune Effect of Radiotherapy: Investigating the mechanisms by which radiation modulates the anti-tumor immune response and strategizing the synergistic combination of radiotherapy with immunotherapy.
• Personalized Radiation Medicine: Developing adaptive and precision treatment planning tailored to individual tumor biology and patient characteristics.

Chairs (cc'ed):

• Prof. Alejandro Bertolet Reina, PhD: Assistant Professor of Radiation Oncology, Massachusetts General Hospital. Director of Radiopharmaceutical Dosimetry.
• Prof. Miguel Antonio Cortés Giraldo, PhD: Profesor Titular, Departamento de Física Atómica, Molecular y Nuclear, Universidad de Sevilla